177 results on '"Shimomura, Tatsuya"'
Search Results
2. Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world
3. A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection
4. A case of uncommon metastasis located posterior to the seminal vesicles in renal cell carcinoma
5. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
6. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study
7. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis
8. Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study
9. Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
10. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis
11. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation
12. Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective study
13. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study.
14. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
15. Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
16. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer
17. Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis–Targeted Agents
18. Clinical significance of intraductal carcinoma of the prostate after high-dose brachytherapy with external beam radiation therapy: A single institution series and an updated meta-analysis
19. Patients with PSA below 0.2 ng/mL at 8 years post high‐dose‐rate brachytherapy have an extremely low risk of subsequent recurrence
20. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
21. Pagetoid spread of urothelial carcinoma controlled without resection
22. Chemical Components in Hedera rhombea Leaves and Their Cytotoxicity
23. Lympho-vascular involvement of seminal vesicle invasion in prostatic adenocarcinoma correlates biochemical recurrence free survival in the radical prostatectomy series: 123
24. Pagetoid spread of urothelial carcinoma controlled without resection.
25. Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
26. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer
27. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
28. Patterns of failure and influence of potential prognostic factors after surgery in transitional cell carcinoma of the upper urinary tract
29. Reduction of Initial Dose of Enzalutamide does not Decrease the Incidence and Severity of Adverse Events in Castration-Resistant Prostate Cancer
30. Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging
31. Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin
32. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer.
33. Extracorporeal shock wave treatment for Peyronieʼs disease using EDAP LT-02; preliminary results
34. Clinical investigation of neuroendocrine differentiation in prostate cancer.
35. MP52-13 NEUROENDOCRINE DIFFERENCIATION OF PROSTATE CANCER AND THE OUTCOMES OF EVEROLIMUS AGAINST NEUROENDOCRINE PROSTATE CANCER (NEPC)
36. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer
37. The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.
38. 去勢抵抗性前立腺癌に対するドセタキセル療法における予後予測因子の検討 (原著)
39. 上部尿路上皮癌における再発パターンならびに予後予測因子に関する検討
40. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer
41. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
42. Treatment outcome of everolimus against neuroendocrine prostate cancer (NEPC).
43. Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy
44. MP47-13 COMPARISON BETWEEN MID-TERM OUTCOMES OF HIGH-DOSE-RATE BRACHYTHERAPY WITH EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY AND RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER.
45. Papillary adenocarcinoma of the prostate: report of 4 cases
46. Does Gleason pattern 5 influence the efficacy of enzalutamide against castration-resistant prostate cancer?
47. EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
48. Bilateral pyeloureteritis cystica: a case report
49. Malignant fibrous histiocytoma of perirenal tissue: a case report
50. Do we need daily corticosteroid combined with docetaxel when treating against castration-resistant prostate cancer?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.